Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value
$47.89+1.42 (+3.06%)
Close on Nov 11, 2026Market cap $8.03BP/E 126.0Yield –
Alkermes ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Alkermes's ebitda for the twelve months ending Jun 30, 2026 was $178.89M, down 55.6% year over year. For fiscal 2025 it was $281.12M, down 37.4% from the year before. The highest annual figure on record is $489.05M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $281.12M | -37.4% |
| FY2024 | Dec 31, 2024 | $449.17M | -8.2% |
| FY2023 | Dec 31, 2023 | $489.05M | +581.4% |
| FY2022 | Dec 31, 2022 | $71.77M | -59.3% |
| FY2021 | Dec 31, 2021 | $176.40M | – |
| FY2020 | Dec 31, 2020 | -$30.57M | – |
| FY2019 | Dec 31, 2019 | -$95.07M | -2197.7% |
| FY2018 | Dec 31, 2018 | $4.53M | – |
| FY2017 | Dec 31, 2017 | -$49.38M | – |
| FY2016 | Dec 31, 2016 | -$114.41M | – |
| FY2015 | Dec 31, 2015 | -$138.71M | -189.2% |
| FY2013 | Mar 31, 2013 | $155.56M | – |
| FY2012 | Mar 31, 2012 | -$40.40M | – |
| FY2011 | Mar 31, 2011 | -$36.98M | – |
| FY2010 | Mar 31, 2010 | -$18.01M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $48.63M | -51.8% |
| Q1 FY2026 | Mar 31, 2026 | -$28.85M | -236.0% |
| Q4 FY2025 | Dec 31, 2025 | $61.95M | -63.5% |
| Q3 FY2025 | Sep 30, 2025 | $97.16M | -13.0% |
| Q2 FY2025 | Jun 30, 2025 | $100.80M | -13.5% |
| Q1 FY2025 | Mar 31, 2025 | $21.21M | -58.7% |
| Q4 FY2024 | Dec 31, 2024 | $169.54M | +131.7% |
| Q3 FY2024 | Sep 30, 2024 | $111.73M | +3.6% |
| Q2 FY2024 | Jun 30, 2024 | $116.54M | -61.2% |
| Q1 FY2024 | Mar 31, 2024 | $51.37M | +563.5% |
| Q4 FY2023 | Dec 31, 2023 | $73.17M | -45.9% |
| Q3 FY2023 | Sep 30, 2023 | $107.86M | – |
| Q2 FY2023 | Jun 30, 2023 | $300.28M | – |
| Q1 FY2023 | Mar 31, 2023 | $7.74M | – |
| Q4 FY2022 | Dec 31, 2022 | $135.27M | -10.2% |
| Q3 FY2022 | Sep 30, 2022 | -$41.04M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.07M | -165.8% |
| Q1 FY2022 | Mar 31, 2022 | -$7.39M | -330.1% |
| Q4 FY2021 | Dec 31, 2021 | $150.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$268.00K | -102.7% |
| Q2 FY2021 | Jun 30, 2021 | $22.90M | – |
| Q1 FY2021 | Mar 31, 2021 | $3.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.40M | -198.3% |
| Q3 FY2020 | Sep 30, 2020 | $9.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.32M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.76M | – |
| Q4 FY2019 | Dec 31, 2019 | $10.58M | -59.2% |
| Q3 FY2019 | Sep 30, 2019 | -$33.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.01M | -162.4% |
| Q1 FY2019 | Mar 31, 2019 | -$56.36M | – |
| Q4 FY2018 | Dec 31, 2018 | $25.92M | -16.5% |
| Q3 FY2018 | Sep 30, 2018 | -$10.89M | – |
| Q2 FY2018 | Jun 30, 2018 | $25.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$36.17M | – |
| Q4 FY2017 | Dec 31, 2017 | $31.05M | +2687.5% |
| Q3 FY2017 | Sep 30, 2017 | -$13.32M | – |
| Q2 FY2017 | Jun 30, 2017 | -$20.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$47.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.11M | – |
| Q3 FY2016 | Sep 30, 2016 | -$37.31M | – |
See a number that looks wrong?